Citi analyst Yigal Nochomovitz downgraded Mirati Therapeutics (MRTX) to Neutral from Buy with a price target of $59, up from $48, after the company announced FTC approval for the pending acquisition by Bristol Myers (BMY) for $58 per share in cash and a CVR worth up to $12 per share. The firm expects the deal to close as planned in Q1 of 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRTX:
- Mirati Therapeutics’ Krazati receives positive opinion in NSLC from CHMP
- Leerink downgrades Mirati to Market Perform as focus remains on acquisition
- Mirati Therapeutics downgraded to Market Perform from Outperform at Leerink
- Mirati Therapeutics downgraded to Hold on pending buyout at Stifel
- Mirati Therapeutics downgraded to Hold from Buy at Stifel
